These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
468 related articles for article (PubMed ID: 34391082)
21. Neuroprotective effect of crocin against rotenone-induced Parkinson's disease in rats: Interplay between PI3K/Akt/mTOR signaling pathway and enhanced expression of miRNA-7 and miRNA-221. Salama RM; Abdel-Latif GA; Abbas SS; El Magdoub HM; Schaalan MF Neuropharmacology; 2020 Mar; 164():107900. PubMed ID: 31811872 [TBL] [Abstract][Full Text] [Related]
22. Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression. Deng J; Bai X; Feng X; Ni J; Beretov J; Graham P; Li Y BMC Cancer; 2019 Jun; 19(1):618. PubMed ID: 31234823 [TBL] [Abstract][Full Text] [Related]
23. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma. Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319 [TBL] [Abstract][Full Text] [Related]
24. Target regulation of PI3K/Akt/mTOR pathway by cannabidiol in treatment of experimental multiple sclerosis. Giacoppo S; Pollastro F; Grassi G; Bramanti P; Mazzon E Fitoterapia; 2017 Jan; 116():77-84. PubMed ID: 27890794 [TBL] [Abstract][Full Text] [Related]
25. Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway. Chen D; Lin X; Zhang C; Liu Z; Chen Z; Li Z; Wang J; Li B; Hu Y; Dong B; Shen L; Ji J; Gao J; Zhang X Cell Death Dis; 2018 Jan; 9(2):123. PubMed ID: 29374144 [TBL] [Abstract][Full Text] [Related]
26. Targeting PI3K-AKT/mTOR signaling in the prevention of autism. Sharma A; Mehan S Neurochem Int; 2021 Jul; 147():105067. PubMed ID: 33992742 [TBL] [Abstract][Full Text] [Related]
27. Bisperoxovanadium Mediates Neuronal Protection through Inhibition of PTEN and Activation of PI3K/AKT-mTOR Signaling after Traumatic Spinal Injuries. Walker CL; Wu X; Liu NK; Xu XM J Neurotrauma; 2019 Sep; 36(18):2676-2687. PubMed ID: 30672370 [TBL] [Abstract][Full Text] [Related]
28. Impairment of insulin signaling pathway PI3K/Akt/mTOR and insulin resistance induced AGEs on diabetes mellitus and neurodegenerative diseases: a perspective review. Ramasubbu K; Devi Rajeswari V Mol Cell Biochem; 2023 Jun; 478(6):1307-1324. PubMed ID: 36308670 [TBL] [Abstract][Full Text] [Related]
29. The PI3K/Akt/mTOR pathway as therapeutic target in neuroblastoma. Fulda S Curr Cancer Drug Targets; 2009 Sep; 9(6):729-37. PubMed ID: 19754357 [TBL] [Abstract][Full Text] [Related]
30. Targeting the PI3K/AKT/mTOR Signaling Pathway in the Treatment of Human Diseases: Current Status, Trends, and Solutions. Huang J; Chen L; Wu J; Ai D; Zhang JQ; Chen TG; Wang L J Med Chem; 2022 Dec; 65(24):16033-16061. PubMed ID: 36503229 [TBL] [Abstract][Full Text] [Related]
31. PI3K/AKT Pathway and Its Mediators in Thyroid Carcinomas. Nozhat Z; Hedayati M Mol Diagn Ther; 2016 Feb; 20(1):13-26. PubMed ID: 26597586 [TBL] [Abstract][Full Text] [Related]
32. Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside. Martelli AM; Tazzari PL; Evangelisti C; Chiarini F; Blalock WL; Billi AM; Manzoli L; McCubrey JA; Cocco L Curr Med Chem; 2007; 14(19):2009-23. PubMed ID: 17691943 [TBL] [Abstract][Full Text] [Related]
33. The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer. Mabuchi S; Kuroda H; Takahashi R; Sasano T Gynecol Oncol; 2015 Apr; 137(1):173-9. PubMed ID: 25677064 [TBL] [Abstract][Full Text] [Related]
34. Angiogenin interacts with ribonuclease inhibitor regulating PI3K/AKT/mTOR signaling pathway in bladder cancer cells. Peng Y; Li L; Huang M; Duan C; Zhang L; Chen J Cell Signal; 2014 Dec; 26(12):2782-92. PubMed ID: 25193113 [TBL] [Abstract][Full Text] [Related]
35. Overview on the Polyphenol Avenanthramide in Oats ( Wankhede NL; Kale MB; Bawankule AK; Aglawe MM; Taksande BG; Trivedi RV; Umekar MJ; Jamadagni A; Walse P; Koppula S; Kopalli SR Nutrients; 2023 Aug; 15(17):. PubMed ID: 37686782 [TBL] [Abstract][Full Text] [Related]
36. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer. Slomovitz BM; Coleman RL Clin Cancer Res; 2012 Nov; 18(21):5856-64. PubMed ID: 23082003 [TBL] [Abstract][Full Text] [Related]
37. Deregulation of PI3K/Akt/mTOR signaling pathways by isoflavones and its implication in cancer treatment. Ahmad A; Biersack B; Li Y; Kong D; Bao B; Schobert R; Padhye SB; Sarkar FH Anticancer Agents Med Chem; 2013 Sep; 13(7):1014-24. PubMed ID: 23272911 [TBL] [Abstract][Full Text] [Related]
38. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma. Beck JT; Ismail A; Tolomeo C Cancer Treat Rev; 2014 Sep; 40(8):980-9. PubMed ID: 25037117 [TBL] [Abstract][Full Text] [Related]